Briefly
Dec 02, 2016

Our Commitment to the Most Common Adult Leukemia

Learn more about the symptoms and treatment of chronic lymphocytic leukemia (CLL).

Stories
Dec 02, 2016

‘Patients Need To Move On With Their Lives’: Q&A With Lori Styles, M.D., Pharmacyclics

Graft-Versus-Host Disease literally adds insult to injury. Preventing it will ensure transplant patients can finally move on with their lives.
 

Briefly
Nov 29, 2016

AbbVie Honored with Global Citizen Award

International Medical Corps celebrates its partnership with AbbVie that brings medical, psycho-social and disaster support to vulnerable populations.
 

Stories
Nov 22, 2016

Need to Win Jeopardy and Conquer Cancer? Call Watson

The global burden of cancer is expected to grow over the next 15 years. Can artificial intelligence help tackle the complexities of the disease?
 
Stories
Nov 22, 2016

What You Don’t Know About Lymphoma and Why It Will Surprise You

Thought to be one disease, non-Hodgkin lymphoma is made up of more than 65 subtypes. Lymphoma Coalition CEO Karen Van Rassel explains the importance of knowing your subtype. 
 

Briefly
Nov 17, 2016

AbbVie Proud of Our National Merit Scholars

We are pleased to participate in the National Merit Scholarship Program to recognize outstanding high school students of our employees’ families. 
 

Briefly
Nov 16, 2016

Five Important Facts About Glioblastoma You Should Know

A particularly aggressive brain cancer called glioblastoma will be a topic of discussion at the Annual Scientific Meeting for the Society for Neuro-Oncology. 
 

Briefly
Nov 15, 2016

Five Things to Know About Lung Cancer

November is Lung Cancer Awareness Month and as the second most common cancer in both men and women, many people have heard of it, but may not know important facts.
 

VIEW ALL STORIES

PRESS RELEASES

Nov 30, 2016

AbbVie Receives Orphan Drug Designation for Investigational IL-23 Inhibitor Risankizumab from the U.S. Food and Drug Administration for the Treatment of Pediatric Patients with Crohn's Disease

 - Orphan Drug Designation program provides orphan status to medications intended for the safe and effective treatment, diagnosis or prevention of rare diseases[1]

Nov 15, 2016

AbbVie's Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) Shows High SVR Rates in Chronic Hepatitis C Patients with Severe Chronic Kidney Disease

NORTH CHICAGO, Ill., Nov. 15, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced 98 percent (n=102/104) of chronic hepatitis C virus (HCV) infected patients with severe chronic kidney disease (CKD) achieved sustained virologic response following 12 weeks of treatment (SVR12) with its investigational, pan-genotypic regimen of glecaprevir (ABT-493)/pibrentasvir (ABT-530) (G/P) in the primary intent-to-treat (ITT) analysis. In a modified intent-to-treat (mITT) analysis, SVR12 was achieved in 100 percent (n=102/102) of severe CKD patients; mITT excludes patients who did not achieve SVR for reasons other than virologic failure. These new data from the Phase 3 EXPEDITION-4 study, evaluating patients with chronic HCV infection across all major genotypes (GT1-6) and severe CKD, will be presented as a late-breaker today at The Liver Meeting®, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston.

Nov 14, 2016

AbbVie's HUMIRA® (Adalimumab) Receives CHMP Positive Opinion to Treat Adolescents with Hidradenitis Suppurativa, a Chronic Inflammatory Skin Disease

NORTH CHICAGO, Ill., Nov. 14, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion for HUMIRA® (adalimumab) for the treatment of active moderate to severe hidradenitis suppurativa (HS) in adolescents from 12 years of age with an inadequate response to conventional systemic HS therapy. If approved, HUMIRA will become the first and only biologic treatment option for patients 12 years of age and older. HUMIRA was approved for adults with moderate to severe HS by the European Commission in July 2015. 

MORE PRESS RELEASES